vs
Kymera Therapeutics, Inc.（KYMR）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Kymera Therapeutics, Inc.的1.2倍（$14.0M vs $11.5M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -667.6%，领先677.4%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -55.3%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-60.6M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 10.1%）
Kymera Therapeutics是一家处于临床阶段的生物制药企业，专注开发创新靶向蛋白降解疗法，推进覆盖肿瘤、自身免疫、炎症类疾病领域的多元化管线，旨在攻克此前无法成药的靶点，满足全球范围的未被满足的医疗需求。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
KYMR vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.2倍
$11.5M
营收增速更快
RVSB
高出65.6%
-55.3%
净利率更高
RVSB
高出677.4%
-667.6%
自由现金流更多
RVSB
多$59.8M
$-60.6M
两年增速更快
RVSB
近两年复合增速
10.1%
损益表 — Q2 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.5M | $14.0M |
| 净利润 | $-76.6M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -736.8% | 12.4% |
| 净利率 | -667.6% | 9.8% |
| 营收同比 | -55.3% | 10.4% |
| 净利润同比 | -82.1% | 11.8% |
| 每股收益（稀释后） | $-0.95 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KYMRRVSB
| Q4 25 | — | $14.0M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $11.5M | $13.3M | ||
| Q1 25 | $22.1M | $12.9M | ||
| Q4 24 | $7.4M | $12.7M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | $25.6M | $12.2M | ||
| Q1 24 | $10.3M | $9.0M |
净利润KYMRRVSB
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-76.6M | $1.2M | ||
| Q1 25 | $-65.6M | $1.1M | ||
| Q4 24 | $-70.8M | $1.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $-42.1M | $966.0K | ||
| Q1 24 | $-48.6M | $-3.0M |
营业利润率KYMRRVSB
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | -736.8% | 11.7% | ||
| Q1 25 | -336.8% | 11.3% | ||
| Q4 24 | -1092.2% | 12.4% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | -198.5% | 10.0% | ||
| Q1 24 | -562.2% | -47.5% |
净利率KYMRRVSB
| Q4 25 | — | 9.8% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | -667.6% | 9.2% | ||
| Q1 25 | -296.7% | 8.9% | ||
| Q4 24 | -956.9% | 9.7% | ||
| Q3 24 | — | 12.2% | ||
| Q2 24 | -164.0% | 7.9% | ||
| Q1 24 | -472.0% | -34.7% |
每股收益（稀释后）KYMRRVSB
| Q4 25 | — | $0.07 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | $-0.95 | $0.06 | ||
| Q1 25 | $-0.82 | $0.05 | ||
| Q4 24 | $-0.89 | $0.06 | ||
| Q3 24 | — | $0.07 | ||
| Q2 24 | $-0.58 | $0.05 | ||
| Q1 24 | $-0.69 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $335.8M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $971.5M | $164.2M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KYMRRVSB
| Q4 25 | — | $28.6M | ||
| Q3 25 | — | $32.8M | ||
| Q2 25 | $335.8M | $34.2M | ||
| Q1 25 | $90.0M | $29.4M | ||
| Q4 24 | $120.3M | $25.3M | ||
| Q3 24 | — | $31.0M | ||
| Q2 24 | $67.6M | $27.8M | ||
| Q1 24 | $93.5M | $23.6M |
股东权益KYMRRVSB
| Q4 25 | — | $164.2M | ||
| Q3 25 | — | $163.5M | ||
| Q2 25 | $971.5M | $162.0M | ||
| Q1 25 | $786.2M | $160.0M | ||
| Q4 24 | $835.6M | $158.3M | ||
| Q3 24 | — | $160.8M | ||
| Q2 24 | $684.9M | $155.9M | ||
| Q1 24 | $711.2M | $155.6M |
总资产KYMRRVSB
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $918.3M | $1.5B | ||
| Q4 24 | $978.0M | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $826.0M | $1.5B | ||
| Q1 24 | $868.3M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.9M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-60.6M | $-736.0K |
| 自由现金流率自由现金流/营收 | -527.9% | -5.2% |
| 资本支出强度资本支出/营收 | 6.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-250.5M | $20.4M |
8季度趋势，按日历期对齐
经营现金流KYMRRVSB
| Q4 25 | — | $-506.0K | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | $-59.9M | $-697.0K | ||
| Q1 25 | $-79.2M | $8.3M | ||
| Q4 24 | $-61.8M | $2.2M | ||
| Q3 24 | — | $764.0K | ||
| Q2 24 | $-42.9M | $5.4M | ||
| Q1 24 | $-39.6M | $12.8M |
自由现金流KYMRRVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $-60.6M | $-773.0K | ||
| Q1 25 | $-79.6M | $5.6M | ||
| Q4 24 | $-62.7M | $1.9M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $-47.6M | $5.3M | ||
| Q1 24 | $-47.0M | $7.1M |
自由现金流率KYMRRVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 120.1% | ||
| Q2 25 | -527.9% | -5.8% | ||
| Q1 25 | -360.3% | 43.1% | ||
| Q4 24 | -848.3% | 15.0% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | -185.7% | 43.7% | ||
| Q1 24 | -456.8% | 79.0% |
资本支出强度KYMRRVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 2.1% | 21.0% | ||
| Q4 24 | 12.7% | 2.4% | ||
| Q3 24 | — | 17.3% | ||
| Q2 24 | 18.3% | 0.9% | ||
| Q1 24 | 72.0% | 62.0% |
现金转化率KYMRRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
